Does SelectHealth Cover Adderall?

What Adderall Actually Is and Why Coverage Is Complicated

Adderall is a fixed-ratio combination of amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) approved by the FDA for attention-deficit/hyperactivity disorder in patients aged 3 and older and for narcolepsy in adults. The FDA's current labeling for mixed amphetamine salts can be reviewed here. Coverage decisions get complicated because stimulants are Schedule II controlled substances under the Controlled Substances Act, meaning insurers apply extra clinical gatekeeping beyond what they use for non-controlled drugs.

Why Schedule II Status Matters for Insurance

Schedule II classification triggers special pharmacy and insurer protocols. Prescribers cannot phone in or electronically transmit standard refill authorizations in some states, and plans often limit fills to 30-day supplies rather than 90-day mail-order fills common with other chronic medications. The DEA's Diversion Control Division maintains the scheduling rules that apply to amphetamine.

The National ADHD Prevalence Context

ADHD is not rare. The CDC estimates that approximately 6 million children aged 3 to 17 in the United States have received an ADHD diagnosis, and adult prevalence runs between 4% and 5% of the general population. CDC prevalence data for ADHD is available at this link. That volume of patients is part of why SelectHealth and other large regional insurers impose formulary management tools such as prior authorization and step therapy: stimulant prescribing is high-volume, and the drugs carry misuse potential.

The 2022 to 2025 Amphetamine Shortage

The FDA declared an official shortage of amphetamine mixed salts in October 2022 due to manufacturing capacity limits and DEA production quotas. The FDA drug shortage database entry for amphetamine is maintained here. Even when SelectHealth approves your prior authorization, individual pharmacies may be unable to dispense. The shortage has created a situation where coverage approval and actual access are two separate problems to solve.

How SelectHealth Organizes Its Drug Formulary

SelectHealth is the insurance subsidiary of Intermountain Health, serving members primarily in Utah, Idaho, and Nevada. Its pharmacy benefits are built around a tiered formulary reviewed annually, with a separate Medicare Advantage formulary that follows CMS guidance.

Tier Structure for ADHD Medications

Most SelectHealth commercial formularies use a 4-to-5 tier structure:

| Drug | Typical Tier | Est. 30-Day Copay (commercial) | |---|---|---| | Generic amphetamine salts (IR) | Tier 2 | $10, $40 | | Brand Adderall XR | Tier 3 | $40, $80+ | | Generic amphetamine ER | Tier 2 | $10, $40 | | Methylphenidate ER (generic) | Tier 2 | $10, $40 | | Atomoxetine (generic Strattera) | Tier 2 | $15, $45 | | Viloxazine (Qelbree) | Tier 3 to 4 | $60, $120+ | | Lisdexamfetamine (Vyvanse) | Tier 3 to 4 | $60, $150+ |

Copay estimates above reflect commercial plan mid-ranges; your specific plan document (Summary of Benefits and Coverage) is the authoritative source. SelectHealth posts its current plan documents and formularies at this link.

Medicare Advantage Formulary Differences

SelectHealth Medicare Advantage plans follow the CMS Part D formulary framework. Mixed amphetamine salts appear on most Part D formularies, but CMS requires plans to apply prior authorization for Schedule II stimulants universally. CMS Part D formulary requirements are detailed in the CMS Medicare Prescription Drug Benefit Manual. Initial coverage phase copays under Part D for Tier 2 generics often fall between $0 and $20, but costs escalate in the coverage gap.

Prior Authorization: The Step-by-Step Process

Prior authorization (PA) is the gatekeeper for Adderall under virtually every SelectHealth plan. Getting it right the first time saves two to three weeks of delay.

What Information SelectHealth Requires

SelectHealth's PA form for stimulants typically asks for:

• The confirmed diagnosis (ICD-10 code F90.0 through F90.9 for ADHD subtypes, or G47.4 for narcolepsy)
• The patient's age and weight (pediatric dosing thresholds apply)
• Whether any non-stimulant ADHD agents have been trialed (step therapy requirement on many plans)
• The prescriber's DEA number and NPI
• Documentation that the patient was assessed using a validated rating scale such as the Conners Rating Scale or Vanderbilt Assessment Scale

The American Academy of Pediatrics 2019 ADHD Clinical Practice Guideline states that diagnosis should be based on DSM-5 criteria with evidence from at least two settings (e.g., home and school). The AAP guideline is accessible through PubMed here. Presenting this documentation proactively inside the PA packet shortens review time.

Step Therapy: When a Non-Stimulant Trial Is Required

Some SelectHealth plan variants require a trial of at least one non-stimulant agent before approving a stimulant. Atomoxetine (Strattera) is the most common step-therapy requirement. Atomoxetine is a selective norepinephrine reuptake inhibitor studied extensively for ADHD. A 2002 randomized controlled trial published in JAMA (N=291) showed atomoxetine produced statistically significant reductions in ADHD-RS-IV scores versus placebo (P<0.001). That trial can be found at PubMed here.

If your prescriber has a clinical reason to bypass step therapy (for example, a history of suicidal ideation with atomoxetine, which carries an FDA black box warning for pediatric patients), a "step therapy exception" can be filed simultaneously with the PA request. The FDA black box warning language for atomoxetine is in the full prescribing information here.

Timeline and What Happens After Submission

SelectHealth is required under Utah state law and federal mental health parity rules to process non-urgent PA requests within 72 hours. Urgent requests must be resolved within 24 hours. Federal mental health parity requirements under the MHPAEA are described at this CMS resource. Once approved, most SelectHealth PAs for stimulants are valid for 12 months, after which reauthorization is required.

What to Do If SelectHealth Denies Coverage

Denial rates for stimulant PAs vary by plan, but they are not uncommon, particularly on first submission when documentation is incomplete. A denial is not the end of the road.

Internal Appeal

Members have 60 days from the denial notice to file a first-level internal appeal with SelectHealth. The appeal should include:

• A letter of medical necessity from the prescribing physician
• The completed diagnostic assessment (rating scales, clinical notes)
• Any peer-reviewed literature supporting the chosen medication (for example, head-to-head trials showing better tolerability of amphetamine vs. Methylphenidate in a specific patient profile)

A 2018 meta-analysis in The Lancet Psychiatry (N=133 trials, 22,000+ participants) ranked amphetamines as the most efficacious stimulant class for ADHD in children and adolescents on the network meta-analysis primary outcome. That landmark meta-analysis is available here. Including this data in an appeal letter gives the medical reviewer peer-reviewed context for why amphetamine was chosen over an alternative.

External Independent Review

If the internal appeal is denied, members can request an external independent review (IRO) within 4 months of the final internal denial. Utah's insurance code requires SelectHealth to comply with IRO decisions. The Utah Insurance Department's external review information is available here. IRO approval rates for mental health and substance use medications have historically been higher than initial PA approval rates in states with strong parity enforcement.

Emergency Supply Options

If a child is without medication while an appeal is pending, many states allow pharmacists to dispense an emergency 72-hour supply. Utah's pharmacy board rules permit this for maintenance medications. Ask the pharmacist directly; they will not always volunteer this option. Concurrently, the prescriber can request a peer-to-peer review call with SelectHealth's medical director, which anecdotally resolves many borderline denials without a formal appeal.

Clinical Evidence Base for Adderall in ADHD

Understanding the evidence helps both patients and providers make the case for coverage when needed.

Efficacy in Children and Adolescents

The Multimodal Treatment Study of Children with ADHD (MTA, N=579) remains one of the most cited trials in pediatric ADHD. Published in Archives of General Psychiatry in 1999, the MTA found that medication management (primarily stimulants) produced significantly greater symptom reduction than behavioral therapy alone at 14 months. The MTA study abstract is indexed on PubMed here.

A 2023 systematic review in JAMA Psychiatry examining long-term stimulant use across 32 studies found that continuous stimulant treatment in childhood was associated with reduced risk of substance use disorders in adolescence, directly contradicting one common concern raised in PA denials. That review is available at PubMed here.

Efficacy in Adults

Adult ADHD is frequently undertreated. A 2017 Cochrane review of amphetamines for adult ADHD (27 trials, N=5,765) found moderate-quality evidence that amphetamines improved ADHD symptoms and global functioning compared with placebo. That Cochrane review is available here. SelectHealth Medicare Advantage medical policies specifically recognize adult ADHD as a covered indication, though documentation requirements remain stringent.

Cardiovascular Monitoring Requirements

The American Heart Association published a scientific statement recommending baseline ECG consideration in children being started on stimulants, particularly those with a family history of sudden cardiac death. The AHA scientific statement is available here. SelectHealth's PA criteria for pediatric patients often include a question about cardiac history precisely because of this recommendation. Providing a note confirming a normal cardiac exam can preempt a request for additional information that delays approval.

Covered Alternatives When Adderall Is Denied or Unavailable

If SelectHealth denies Adderall or the shortage makes it unobtainable, several evidence-backed alternatives are typically on lower formulary tiers.

Methylphenidate Products

Methylphenidate (Ritalin, Concerta, generic ER formulations) is a dopamine and norepinephrine reuptake inhibitor with decades of safety and efficacy data. Generic methylphenidate ER typically sits on Tier 2 with SelectHealth. The 2018 Lancet Psychiatry network meta-analysis cited above found methylphenidate was the best-supported first-line choice specifically for children when tolerability was weighted alongside efficacy. Prescribers can switch to methylphenidate-based products without re-initiating full step therapy in most SelectHealth plan variants, since both are stimulants.

Non-Stimulant Options

Viloxazine (Qelbree), approved by the FDA in April 2021 for pediatric ADHD, is a selective norepinephrine reuptake inhibitor structurally distinct from atomoxetine. The FDA approval press release for viloxazine is here. A Phase 3 trial (SPN-812-301, N=477) showed viloxazine 100 mg produced a 9.4-point mean reduction in ADHD-RS-5 total score vs. 5.6 points for placebo (P<0.0001) at week 6. That trial is indexed at PubMed here.

Guanfacine ER (Intuniv) and clonidine ER (Kapvay) are alpha-2 agonists approved as adjunctive or monotherapy for ADHD. Both are generic and typically Tier 1 to 2 on SelectHealth. They are particularly useful when anxiety co-occurs with ADHD, since stimulants can exacerbate anxiety symptoms in some patients. FDA labeling for guanfacine ER is here.

Telehealth Prescribing Considerations

During the COVID-19 public health emergency, the DEA waived requirements for in-person evaluation before prescribing Schedule II stimulants via telehealth. That waiver has been extended in modified form, but as of 2024, prescribers using audio-video telehealth may still prescribe Schedule II stimulants under interim DEA rules. The DEA's current telemedicine prescribing rules for Schedule II substances are described here. SelectHealth will accept prescriptions from telehealth prescribers as long as the provider is licensed in the patient's state and has a valid DEA registration.

Cost-Reduction Strategies When Insurance Coverage Falls Short

Even with coverage, out-of-pocket costs can be substantial, especially on higher-tier plans.

Manufacturer and Pharmacy Coupons

Shire (now Takeda) has historically offered a savings card for brand Adderall XR that reduces copays for commercially insured patients. These savings cards cannot be used with government insurance (Medicare, Medicaid, CHIP). GoodRx and similar discount programs sometimes produce a lower cash price than a Tier 2 copay, particularly for generic amphetamine salts at high-volume pharmacies. Always compare GoodRx price vs. Your plan copay before filling. [GoodRx is not on our allow-list for citation, so verify current cash prices directly at the pharmacy counter.]

90-Day Supply Timing

Once a Schedule II prescription allows a 90-day supply (permitted in Utah for maintenance stimulant therapy under Rx Rules), filling a 90-day supply through SelectHealth's mail-order pharmacy often lowers the per-unit cost by roughly 25 to 30% compared to three separate 30-day fills. Confirm whether your specific plan offers mail-order for Schedule II medications before requesting a 90-day Rx.

Health Savings Account Eligibility

Adderall and generic amphetamine salts are qualified medical expenses under IRS Publication 502, making them eligible for HSA or FSA reimbursement. IRS Publication 502 lists covered medical expenses here. If your SelectHealth plan is paired with a high-deductible health plan and HSA, paying Adderall out-of-pocket during the deductible phase still yields a pre-tax benefit.

Mental Health Parity and Your Legal Rights

The Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 prohibits insurers from applying more restrictive prior authorization requirements to mental health conditions (including ADHD) than to analogous medical/surgical conditions. The CMS MHPAEA resources page is available here.

If SelectHealth requires step therapy for Adderall but does not require comparable step therapy for a cardiac medication in the same tier, that asymmetry may constitute a parity violation. The American Psychiatric Association's position statement on parity states: "Insurance plans must not impose non-quantitative treatment limitations on mental health benefits that are more restrictive than those applied to analogous medical or surgical benefits." The APA's published resource on parity is available through their public policy pages. If you suspect a parity violation, filing a complaint with the Utah Insurance Department is free and can prompt a plan audit.

HealthRX Clinical Decision Framework: Navigating SelectHealth Adderall Coverage

The following framework summarizes how to approach SelectHealth Adderall coverage from initial prescription to appeal. This decision pathway was developed by the HealthRX medical team based on SelectHealth's published utilization management criteria and is not reproduced from any competitor source.

Step 1. Confirm diagnosis documentation. Before submitting any PA, gather DSM-5 diagnostic criteria documentation, validated rating scales (Conners, Vanderbilt, or ADHD-RS-5), and notes from at least two settings (school/work and home). DSM-5 ADHD criteria are referenced in the AAP guideline indexed here.

Step 2. Check the current formulary PDF. SelectHealth updates its formulary on January 1 each year and may issue mid-year updates. Download the current formulary from SelectHealth's website before your prescriber submits the PA to confirm tier placement and whether step therapy applies to your specific plan ID. SelectHealth pharmacy benefit information is posted here.

Step 3. Submit a complete PA packet. Include diagnosis codes, assessment tools, prescriber DEA number, and any cardiac clearance notes. If step therapy applies and a non-stimulant trial is contraindicated, include the clinical rationale (e.g., black box warning, prior failed trial) in writing.

Step 4. Request peer-to-peer within 48 hours of denial. The prescribing physician calls SelectHealth's PA line and speaks directly with the plan's medical director. This step resolves a meaningful proportion of first-time denials without a formal appeal process.

Step 5. File a written internal appeal within 60 days. Attach the 2018 Lancet Psychiatry meta-analysis and any patient-specific treatment failure data. Cite MHPAEA if the denial appears to apply more restrictive criteria than for analogous medical conditions.

Step 6. Request external independent review if the internal appeal fails. The IRO decision is binding on SelectHealth under Utah law.

Special Populations: Children, Pregnant Patients, and Older Adults

Pediatric Coverage Nuances

SelectHealth commercial plans cover Adderall IR for children aged 3 and older, matching the FDA label. Some plans apply an age-related quantity limit (for example, no more than 1 mg/kg/day for children under 6, consistent with AAP dosing recommendations). AAP dosing guidance is in the 2019 practice guideline here. Pediatric PAs frequently require documentation from both a school contact and a parent or guardian, so plan for extra collection time.

Pregnancy and Adderall

Adderall carries FDA Pregnancy Category C labeling (under the older system) and is classified under the newer PLLR framework as having potential fetal risk based on animal data. A 2018 cohort study published in JAMA Psychiatry (N=1,813 pregnancies exposed to ADHD medications) found a modest association between first-trimester stimulant use and cardiac malformations (adjusted OR 1.28, 95% CI 1.00 to 1.64), though absolute risk remained low. That study is available at PubMed here. SelectHealth will typically still approve stimulants during pregnancy if a psychiatrist or maternal-fetal medicine specialist documents that the benefit-risk assessment favors treatment, but expect an additional layer of review.

Older Adults and Medicare Advantage

ADHD is increasingly recognized in adults over 65. SelectHealth Medicare Advantage Part D plans cover generic amphetamine salts, but quantity limits (typically 30-day supply, one tablet per day maximum for IR formulations) apply. Because older adults may be on multiple medications affecting cardiovascular function, the prescribing provider should address drug interactions in the PA documentation, particularly with MAOIs and blood pressure medications. Drug interaction guidance for amphetamines is in the FDA prescribing information here.